The combination of everolimus (a mTOR inhibitor) and 5-aza-2-deoxycytidine (a demethylating agent) can effectively inhibit the production of ovarian clear-cell cancer stem-like or spheroid cells by inhibiting the COL6A3-AKT-mTOR pathway and exerting an anti-tumor effect [26]. The gene discussed is COL6A3; the disease is ovarian clear cell cancer.